Document Detail


Impact of host and virus genome variability on HCV replication and response to interferon.
MedLine Citation:
PMID:  23835049     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Since the discovery of hepatitis C virus (HCV), treatment has proven difficult and the regimen of pegylated interferon-α and ribavirin is only effective for half of patients. Evidence suggests that host and viral genome variations play a role in either viral clearance or persistence. Powerful genomic technologies have made it possible to study genome-wide associations with treatment response, which yielded critical genetic polymorphisms that predict treatment response. This has important implications for treatment of HCV infection and opened the door to the possibility of genetic marker-guided treatment (personalized medicine). This review will focus on the recent advances in understanding host and viral genetic variations with regards to treatment and the importance for future therapeutic intervention.
Authors:
Cameron J Schweitzer; T Jake Liang
Related Documents :
23939239 - Evidence for continuing cross-species transmission of sivsmm to humans: characterizatio...
23433339 - Policy development, implementation and evaluation by the aids control program in uganda...
23415569 - Manifestations of hiv infection in the peripheral nervous system.
20408389 - Enrollment in outpatient care among newly released prison inmates with hiv infection.
20207669 - Inmates with hiv, stigma, and disclosure decision-making.
24233329 - Sexual risk for hiv among gay male couples: a longitudinal study of the impact of relat...
12974899 - Transforming growth factor-beta-1 genetic polymorphism in japanese patients with chroni...
16709329 - Correlation of cd4 count, cd4% and hiv viral load with clinical manifestations of hiv i...
2338619 - Model-based optimization of infectivity parameters: a study of the early epidemic in sa...
Publication Detail:
Type:  Journal Article; Review     Date:  2013-07-06
Journal Detail:
Title:  Current opinion in virology     Volume:  3     ISSN:  1879-6265     ISO Abbreviation:  Curr Opin Virol     Publication Date:  2013 Oct 
Date Detail:
Created Date:  2013-10-14     Completed Date:  2014-04-30     Revised Date:  2014-10-09    
Medline Journal Info:
Nlm Unique ID:  101560941     Medline TA:  Curr Opin Virol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  501-7     Citation Subset:  IM    
Copyright Information:
Published by Elsevier B.V.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Antiviral Agents / therapeutic use*
Genetic Variation / drug effects
Genome, Viral / drug effects*
Hepacivirus / drug effects*,  genetics,  physiology
Hepatitis C / drug therapy*,  genetics*,  virology
Humans
Interferon-alpha / therapeutic use
Treatment Outcome
Virus Replication / drug effects*
Grant Support
ID/Acronym/Agency:
Z99 DK999999/DK/NIDDK NIH HHS; ZIA DK054504-15/DK/NIDDK NIH HHS; ZIA DK054504-16/DK/NIDDK NIH HHS; ZIA DK054505-15/DK/NIDDK NIH HHS; ZIA DK054505-16/DK/NIDDK NIH HHS; ZIA DK054511-05/DK/NIDDK NIH HHS; ZIA DK054511-06/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  To dream the impossible dream: universal influenza vaccination.
Next Document:  Cognitive dysfunction associated with anti-glutamic acid decarboxylase autoimmunity: a case-control ...